Families Of Spinal Muscular Atrophy Announces Latest Developments On Three SMA Drug Discovery Programs

Families of Spinal Muscular Atrophy has just released details of the latest developments for the Families of SMA funded therapeutic pipeline. Families of SMA is currently funding three distinct drug discovery programs: 1) Quinazolines to boost gene expression; 2) Tetracyclines at Paratek Pharmaceuticals to correct gene splicing; and 3) Motor neuron replacement program at California Stem Cell and UCI.

More: continued here

Filed under: Muscular Dystrophy on June 25th, 2009